Scientists invent cryomicroneedles for intradermal therapeutic cell delivery

The study was led by Dr Xu Chenjie, Associate Professor at the Department of Biomedical Engineering (BME) at CityU. The latest findings have been published in the scientific journal Nature Biomedical Engineering, titled "Cryomicroneedles for Transdermal Cell Delivery."

The new technology "cryomicroneedles" are the icy microneedles shorter than 1mm and can deliver therapeutic cells into the skin layers. "It is a skin patch-like device that can load, store, and intradermally deliver the living mammalian cells," explained Dr Xu.

Cell therapy, also called cell transplantation, is a therapy in which living cells like immune cells or stem cells are injected, grafted or implanted into a patient to achieve a medicinal effect. Advances in cell therapies have brought promising treating approach for previously intractable diseases like cancers. The global market size of cell therapy was valued at USD 7.8 billion in 2020.

"But many problems related to the application of cell therapy yet to be solved," said Dr Xu. For example, the therapeutic cells are currently delivered by either surgical grafts or bolus injection. These methods are invasive, painful, complicated, low-efficient, and they bring the risk of infection and require experienced professionals to implement. It is also hard to store and transport the current solution-like formulations of cell therapeutics.

To solve this challenge, Dr Xu and his team at CityU have developed these cryomicroneedles that carry and deliver living cells into the skin. By putting the patch-like device on the skin, the microneedles would penetrate through the skin, detach from the patch base and then melt. The loaded cells were released, and subsequently migrated and proliferated inside the skin. This innovative device can be stored for months in refrigerators. It is also easy for transportation and deployment.

As a proof-of-concept, the researchers explored cell-based cancer immunotherapy through intradermal delivery of ovalbumin-pulsed dendritic cells. In the study, vaccination with this device elicited robust antigen-specific immune responses and provided strong protection against tumour in mice, which were superior to the therapeutic outcomes by conventional standard vaccination methods such as subcutaneous and intravenous injection.

"The application of our device is not limited to the delivery of cells. This device can also package, store, and deliver other types of bioactive therapeutic agents, such as proteins, peptides, mRNA, DNA, and vaccines. I hope this device offers an easy-to-use and effective alternative method for the delivery of therapeutics in clinics," Dr Xu said.

Dr Chang Hao from CityU's BME is the first author, and Dr Xu is the corresponding author. Professor Wang Dongan and Dr Shi Peng from BME are also part of the research team. Other researchers come from Nanyang Technological University and National University of Singapore. The research was partially funded by the CityU and a patent application has been filed through CityU.